CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today it will present for the first time, new clinical data for its digital therapeutic utilizing gamma frequency neuromodulation in Alzheimer’s Disease, at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), held virtually March 9-14, 2021.
Details of the symposium panel are below:
Symposium title: Gamma sensory stimulation, a novel AD therapeutic intervention: initial safety, efficacy and biomarker changes from two prospective clinical studies |
|
Date/Time: |
Friday, March 12, 10:00 – 11:00 am ET, followed by Live Q&A |
Moderator: |
Dr. Li-Huei Tsai, neuroscientist and the Director of the Picower Institute for Learning and Memory in the Department of Brain and Cognitive Sciences at MIT |
Panelists: |
Dr. James Lah, Principal Investigator of the Flicker study, and Director of the Cognitive Neurology Program, Emory University |
Dr. Tom Megerian, Chief Medical Officer, Cognito Therapeutics |
|
Dr. Suzanne Hendrix, CEO, Pentara Corporation |
|
A replay of the symposium panel will be posted on Cognito’s website at www.cognitotx.com.
About Cognito Therapeutics
Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimer’s disease. The company’s licensed proprietary neuromodulation platform technology, developed by scientific founders at MIT, Professors Li-Huei Tsai and Ed Boyden is a non-invasive therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases. The company is based in Boston and San Francisco. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
